| scholarly article | Q13442814 |
| P50 | author | Stephan J Reshkin | Q42730260 |
| Anita Mangia | Q54387295 | ||
| Valeria Casavola | Q57601567 | ||
| P2093 | author name string | A Paradiso | |
| M Correale | |||
| T Tedone | |||
| P2860 | cites work | Immunohistochemical determination of pS2 in invasive breast carcinomas: a study on 942 cases | Q71989492 |
| [PS2 as a prognostic factor in 1065 cases of human breast cancer. A multicenter study] | Q72126273 | ||
| Expression of the pS2 protein and correlation with estrogen receptor status in fine-needle aspirates from breast carcinomas | Q72389354 | ||
| Revision of the standards for the assessment of hormone receptors in human breast cancer; report of the second E.O.R.T.C. workshop, held on 16–17 March, 1979, in the Netherlands Cancer Institute | Q72890705 | ||
| Release of the aspartyl protease cathepsin D is associated with and facilitates human breast cancer cell invasion | Q73626803 | ||
| A novel 25 bp tandem repeat within the human trefoil peptide gene TFF2 in 21q22.3: polymorphism and mammalian evolution | Q28286072 | ||
| The 5' flanking region of the pS2 gene contains a complex enhancer region responsive to oestrogens, epidermal growth factor, a tumour promoter (TPA), the c-Ha-ras oncoprotein and the c-jun protein | Q33561391 | ||
| A human cell line from a pleural effusion derived from a breast carcinoma | Q34207627 | ||
| Prediction of relapse and survival in breast cancer patients by pS2 protein status | Q34643233 | ||
| pS2 is an independent factor of good prognosis in primary breast cancer | Q35976164 | ||
| PS2 in breast cancer--alternative or complementary tool to steroid receptor status? Evaluation of 446 cases | Q35977131 | ||
| pNR-2/pS2 immunohistochemical staining in breast cancer: correlation with prognostic factors and endocrine response | Q35984246 | ||
| Pathological and biological features of mammographically detected invasive breast carcinomas | Q36079849 | ||
| Relationship of PS2 with response to tamoxifen therapy in patients with recurrent breast cancer | Q36080684 | ||
| pS2 protein: a marker improving prediction of response to neoadjuvant tamoxifen in post-menopausal breast cancer patients | Q36141002 | ||
| Induction of estrogen independence of ZR-75-1 human breast cancer cells by epigenetic alterations | Q36677696 | ||
| Prognostic value of PS2 and cathepsin D in 710 human primary breast tumors: multivariate analysis | Q36782116 | ||
| Differential Metabolism of Large and Small Poly(A) Sequences in the Heterogeneous Nuclear RNA of HeLa Cells | Q37428898 | ||
| The pS2 gene, mRNA, and protein: a potential marker for human breast cancer | Q37974748 | ||
| Dimerization of human pS2 (TFF1) plays a key role in its protective/healing effects | Q41013107 | ||
| Differential responsiveness of proliferation and cytokeratin release to stripped serum and oestrogen in the human breast cancer cell line, MCF-7. | Q41200114 | ||
| Molecular physiology of vertebrate Na+/H+ exchangers | Q41336654 | ||
| Effect of basic fibroblast growth factor on synthesis/secretion of pS2 protein by human breast cancer cells (MCF-7). | Q41431115 | ||
| Distinct effects of gonadotropin-releasing hormone analogs and 4-hydroxytamoxifen on pS2 mRNA expression with respect to cell proliferation in MCF-7 breast cancer cells | Q41704881 | ||
| Prognostic relevance of pS2 status in association with steroid receptor status and proliferative activity in node-negative breast cancer. | Q44298561 | ||
| Enzyme-linked immunosorbent assay of pS2 in breast cancers, benign tumors, and normal breast tissues. Correlation with prognosis and adjuvant hormone therapy | Q44556147 | ||
| Effect of tumor size on the association between ps2 and cathepsin-d in primary breast-cancer. | Q47361530 | ||
| Characterization of the estrogen-induced pS2 protein secreted by the human breast cancer cell line MCF-7. | Q54132129 | ||
| Autocrine and paracrine growth regulation of human breast cancer | Q61625136 | ||
| Oestrogen-regulated genes in breast cancer: Association of pLIV1 with lymph node involvement | Q64019081 | ||
| Inhibition of human breast cancer cell (MCF-7) growth in vitro by the somatostatin analog SMS 201-995: effects on cell cycle parameters and apoptotic cell death | Q68035742 | ||
| pS2 expression and response to hormonal therapy in patients with advanced breast cancer | Q68179309 | ||
| pS2 expression in primary breast carcinomas: relationship to clinical and histological features and survival | Q68201722 | ||
| Regulation of cathepsin-D and pS2 gene expression by growth factors in MCF7 human breast cancer cells | Q69518256 | ||
| Hormonal regulation of synthesis and secretion of pS2 protein relevant to growth of human breast cancer cells (MCF-7) | Q69626862 | ||
| Cytosolic levels of estrogen-regulated pS2 protein in breast cancer: correlation with tumor proliferative activity | Q70715599 | ||
| P433 | issue | 2-3 | |
| P304 | page(s) | 107-118 | |
| P577 | publication date | 1999-04-01 | |
| P1433 | published in | Cell Proliferation | Q1952798 |
| P1476 | title | Association of pS2 (TFF1) release with breast tumour proliferative rate: in vitro and in vivo studies | |
| P478 | volume | 32 |
| Q43799792 | Infiltrating ductal carcinomas of the breast in women over 60 years of age. Association with higher cellular proliferation and lower PS2, cell surface and cytosolic hyaluronic acid concentrations |
| Q77306145 | Predictors of distant metastasis at presentation in breast cancer: a study also evaluating associations among common biological indicators |
| Q39508650 | Trefoil factor 1 stimulates both pancreatic cancer and stellate cells and increases metastasis |
Search more.